FRANKFURT (Reuters) – BioNTech, which recently announced promising results from a vaccine developed with Pfizer, plans to market the two doses required at a price lower than that usually charged on the market and which will be adapted according to countries and regions. regions of the world.
Ryan Richardson, chief strategy officer at BioNTech, told an online event hosted by the Financial Times that the price of the vaccine, which has yet to get all regulatory clearances, would reflect the financial risks taken by its private investors.
“We plan (…) to set the price of our vaccine well below the usual market prices in order to reflect the situation in which we find ourselves, and with the aim of ensuring wide worldwide distribution”, he said. -he says.
The European Commission is due to give the green light on Wednesday to the signing of a contract for the purchase of several hundred million doses of this vaccine.
With the contribution of Matthias Blamont, French version Olivier Cherfan, edited by Jean-Michel Bélot